Michael Owen
Director/Board Member chez SAREUM HOLDINGS PLC
Fortune : 727 650 $ au 31/03/2024
Postes actifs de Michael Owen
Sociétés | Poste | Début | Fin |
---|---|---|---|
RENEURON GROUP PLC | Director/Board Member | 04/12/2015 | - |
Independent Dir/Board Member | 04/12/2015 | - | |
SAREUM HOLDINGS PLC | Director/Board Member | 13/11/2018 | - |
European Molecular Biology Organization | Corporate Officer/Principal | - | - |
Ossianix Uk Ltd. | Director/Board Member | - | - |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Director/Board Member | - | - |
Independent Dir/Board Member | - | - | |
The Club Cricket Organisation Ltd. | Director/Board Member | - | - |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | 15/08/2016 | - |
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Director/Board Member | 24/07/2000 | - |
The European Molecular Biology Laboratory | Corporate Officer/Principal | - | - |
░░░░░░░░░ ░░░░ | ░░░░░░░░ | - | - |
░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Historique de carrière de Michael Owen
Anciens postes connus de Michael Owen
Sociétés | Poste | Début | Fin |
---|---|---|---|
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░ ░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ | |
░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formation de Michael Owen
University of Oxford | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 16 |
Allemagne | 3 |
Danemark | 2 |
Opérationnelle
Director/Board Member | 14 |
Independent Dir/Board Member | 4 |
Corporate Officer/Principal | 3 |
Sectorielle
Health Technology | 13 |
Consumer Services | 4 |
Miscellaneous | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 5 |
---|---|
SAREUM HOLDINGS PLC | Miscellaneous |
RENEURON GROUP PLC | Health Technology |
GSK PLC | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
AVACTA GROUP PLC | Commercial Services |
Entreprise privées | 12 |
---|---|
ReNeuron Ltd.
ReNeuron Ltd. BiotechnologyHealth Technology ReNeuron Ltd. researches and develops drugs, diagnostics, and other therapeutic products. The company was founded on May 23, 1997 and is headquartered in Bridgend, the United Kingdom. | Health Technology |
European Molecular Biology Organization | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Iksuda Therapeutics Ltd.
Iksuda Therapeutics Ltd. BiotechnologyHealth Technology Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom. | Health Technology |
Ossianix, Inc.
Ossianix, Inc. Pharmaceuticals: GenericHealth Technology Ossianix, Inc. develops single domain antibodies. It develops biotherapeutic products using the versatile single domain VNAR antibody from the shark and also developed highly innovative approaches to target specific cells and tissues such as the brain via the blood brain barrier and peripheral nerve via the neuromuscular junction. The company was founded by Frank S. Walshin, J. Lynn Rutkowski and Corey S. Goodman in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
BliNK Therapeutics Ltd.
BliNK Therapeutics Ltd. BiotechnologyHealth Technology BliNK Therapeutics Ltd. is a holding company which produces monoclonal antibodies using a novel platform. The platform technology provides a new way of activating the immune system’s B cells to produce antibodies in response to a specific antigen. The company was founded in 2011 and is headquartered in Marlow, the United Kingdom. | Health Technology |
BliNK Biomedical SAS
BliNK Biomedical SAS BiotechnologyHealth Technology BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Avacta Life Sciences Ltd.
Avacta Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Avacta Life Sciences Ltd. provides powerful reagents for research and diagnostics. The company is headquartered in Wetherby, the United Kingdom. | Health Technology |
The Club Cricket Organisation Ltd. | |
Ossianix Uk Ltd. | |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The private company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Michael Owen
- Expérience